HLA-DRB1 gene polymorphism in patients with dilated cardiomyopathy

Abstract

To probe into the genetic background and immunopathogenesis of dilated cardiomyopathy (DCM), HLA-DRBl gene polymorphism in 68 patients with DCM and 175 normal control subjects were analyzed by using the polymerase chain reaction/sequence specific primer (PCR/SSP) techniques. It was found that the frequencies of HLA-DRBl * 15 and HLA-DRBl * 03 alleles were significantly lower in DCM patients than those in normal controls (14.71% vs 29.71% and 4.41% vs 15.43%, respectively), the relative risks (RR) in the DCM patients being 0.41 and 0.25, respectively, allP>0.05. However, the frequencies of HLA-DRBl 11 and HLA-DRB1* 12 alleles were significantly higher in the DCM patients than in controls (29.4% vs 12.00% and 36. 76% vs 12. 57%, respectively) with the RR in the DCM patients being 3.06 and 4.04, respectively, allP>0. 01. These findings further demonstrated that-immunogenetics might play a predominant pathogenetic role in partial DCM patients.

Keywords

dilated cardiomyopathy / HLA antibody

References

[1] SchmidtM A, MickeisV V, EdwardsW D, et al.. Familial dilated cardiomyopathy. Am J Med Genet, 1988, 31: 135-135

[2] MichelsV V, MollP P, MillerF A, et al.. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med, 1992, 326: 77-77

[3] LiaoY H. Functional analysis of autoantibodies against ADP/ATP carrier from dilated cardiomyopathy. Int J Cardiol, 1996, 54: 165-165

[4] ThomsonG. HLA and disease association: Models for insulin dependent diabetes mellitus and the study of complex genetic disorders. Ann Rev Genet, 1988, 22: 31-31

[5] GregersenP K. Biology of disease. HLA class I polymorphism; implications for genetic susceptibility to autoimmune disease. Lab Invest, 1989, 61: 5-5

[6] BodmerL G, MarshS G E, AlbertED, et al.. Nomenclature for factors of the HLA system. Tissue Antigens, 1994, 44: 1-1

[7] BrandenburgR O, ChazovE, CherianG, et al.. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J, 1980, 44: 672-672

[8] OlerupO, ZetterquistH. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantations. Tissue Antigens, 1992, 39: 225-225

[9] CaforioA L, GoldmanJ H, HavenA J, et al.. Evidence for autoimmunity to myosin and other heart-specific autoantigens in patients with dilated cardiomyopathy and their relatives. Int J Cardiol, 1996, 54: 157-157

[10] LimasC J, LimasC, KuboS H, et al.. Anti-Beta-Receptor antibodies in human dilated cardiomyopathy and correlation with HLA-DR antigens. Am J Cardiol, 1990, 65: 483-483

[11] AndersonJ L, CarlquistJ F, LutzJ R, et al.. HLA-A, B and DR typing in idiopathic dilated cardiomyopathy: A search for immune response factors. Am J Cardiol., 1984, 53: 1326-1326

[12] CarlquistJ F, MonloveR L, MurrayM B, et al.. HLA Class I (DR and DQ) antigen associations in idiopathic dilated cardiomyopathy. Circulation, 1991, 83: 515-515

[13] ArbustiniE, GavazziA, PozziR, et al.. The morphologic-spectrum of dilated cardiomyopathy and it’s relation to immune response genes. Am J Cardiol, 1989, 64: 991-991

[14] LimasC J, LimasC, GoldenbergI F, et al.. Possible in volvement of the HLA-DQB1 gene in susceptibility and resistance to human dilated cardiomyopathy. Am Heart J, 1995, 129: 1141-1141

[15] OsaA, AlmenarL, PalenciaM, et al.. Antigens of the major histocompatibility system in ischemic heart disease and idiopathic dilated cardiomyopathy. Clin Cardiol., 1999, 22: 292-292